Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs

Эпизоды

Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
31 окт 2017· FierceBiotech Radio
FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of the scientists, account associates and operations managers who competed in 2017's Battle of the Biotech Bands.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
18 мар 2016· FierceBiotech Radio
Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Пропущенные эпизоды?

Нажмите здесь, чтобы обновить ленту.
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
26 фев 2016· FierceBiotech Radio
Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
18 фев 2016· FierceBiotech Radio
Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
11 фев 2016· FierceBiotech Radio
Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
4 фев 2016· FierceBiotech Radio
Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
8 янв 2016· FierceBiotech Radio
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
10 дек 2015· FierceBiotech Radio
Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoughtful consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
3 дек 2015· FierceBiotech Radio
In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles
24 ноя 2015· FierceBiotech Radio
Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering conclusion of two hostile takeovers.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit
12 ноя 2015· FierceBiotech Radio
Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Fraud's not that big of a deal: the Valeant story, according to Bill Ackman
5 ноя 2015· FierceBiotech Radio
Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs
29 окт 2015· FierceBiotech Radio
Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biotech IPOs.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Doomsdays for Valeant, Biogen and biotech VC
22 окт 2015· FierceBiotech Radio
Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand
15 окт 2015· FierceBiotech Radio
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot
8 окт 2015· FierceBiotech Radio
Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud
1 окт 2015· FierceBiotech Radio
Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech bubble, and Bristol-Myers Squibb's interesting televisual choices.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
John Carroll on Turing Pharma and Martin Shkreli
22 сен 2015· FierceBiotech Radio
FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Martin Shkreli's public response.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Lilly and Boehringer's 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic
18 сен 2015· FierceBiotech Radio
Fierce editors discuss some surprising trial results for a diabetes drug from Eli Lilly and Boehringer Ingelheim, the continued flow of money into private biotech companies, and the public frankness of Roche CEO Severin Schwan.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites
11 сен 2015· FierceBiotech Radio
Fierce editors discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug patents, and a new twist in the buyout battle between Horizon Pharma and Depomed.
- Слушать Слушать снова Продолжить Воспроизведение ...
- Слушать позже Слушать позже
Показать больше

Эпизоды

Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands

GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals

Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup

The burning hole in Gilead's $25B pocket and AbbVie's future in hematology

Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place

The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles

Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit

Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

Doomsdays for Valeant, Biogen and biotech VC

Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud

John Carroll on Turing Pharma and Martin Shkreli

Lilly and Boehringer's 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic

GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites